Testicular Cancer

News alerts, weekly reports and conference planners

Related cancers:

‹

Testicular Seminoma (7)

›

No biomarker	Testicular Cancer	No biomarker	Testicular Cancer	etoposide IV Sensitive: A1 - Approval etoposide IV Sensitive : A1	etoposide IV Sensitive: A1 - Approval etoposide IV Sensitive : A1
No biomarker	Testicular Cancer	No biomarker	Testicular Cancer	cisplatin Sensitive: A1 - Approval cisplatin Sensitive : A1	cisplatin Sensitive: A1 - Approval cisplatin Sensitive : A1
No biomarker	Testicular Cancer	No biomarker	Testicular Cancer	ifosfamide Sensitive: A1 - Approval ifosfamide Sensitive : A1	ifosfamide Sensitive: A1 - Approval ifosfamide Sensitive : A1
No biomarker	Testicular Seminoma	No biomarker	Testicular Seminoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Testicular Seminoma	No biomarker	Testicular Seminoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Testicular Seminoma	No biomarker	Testicular Seminoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Testicular Seminoma	No biomarker	Testicular Seminoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Testicular Seminoma	No biomarker	Testicular Seminoma	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2
No biomarker	Testicular Seminoma	No biomarker	Testicular Seminoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
TMB-H	Testicular Seminoma	TMB-H	Testicular Seminoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Testicular Cancer	No biomarker	Testicular Cancer	gemcitabine + paclitaxel Sensitive: A2 - Guideline gemcitabine + paclitaxel Sensitive : A2	gemcitabine + paclitaxel Sensitive: A2 - Guideline gemcitabine + paclitaxel Sensitive : A2
MSI-H/dMMR	Testicular Cancer	MSI-H/dMMR	Testicular Cancer	cemiplimab-rwlc Sensitive: A2 - Guideline cemiplimab-rwlc Sensitive : A2	cemiplimab-rwlc Sensitive: A2 - Guideline cemiplimab-rwlc Sensitive : A2
TMB-H	Testicular Cancer	TMB-H	Testicular Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
No biomarker	Testicular Cancer	No biomarker	Testicular Cancer	etoposide oral Sensitive: A2 - Guideline etoposide oral Sensitive : A2	etoposide oral Sensitive: A2 - Guideline etoposide oral Sensitive : A2
No biomarker	Testicular Cancer	No biomarker	Testicular Cancer	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Testicular Cancer	No biomarker	Testicular Cancer	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Testicular Cancer	No biomarker	Testicular Cancer	carboplatin + etoposide IV Sensitive: A2 - Guideline carboplatin + etoposide IV Sensitive : A2	carboplatin + etoposide IV Sensitive: A2 - Guideline carboplatin + etoposide IV Sensitive : A2
No biomarker	Testicular Cancer	No biomarker	Testicular Cancer	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Testicular Cancer	No biomarker	Testicular Cancer	BNT211 Sensitive: B - Late Trials BNT211 Sensitive : B	BNT211 Sensitive: B - Late Trials BNT211 Sensitive : B
CLDN6 expression	Testicular Cancer	CLDN6 expression	Testicular Cancer	TORL-1-23 Sensitive: C3 – Early Trials TORL-1-23 Sensitive : C3	TORL-1-23 Sensitive: C3 – Early Trials TORL-1-23 Sensitive : C3
CHEK2 mutation	Testicular Cancer	CHEK2 mutation	Testicular Cancer	talazoparib Sensitive: C4 – Case Studies talazoparib Sensitive : C4	talazoparib Sensitive: C4 – Case Studies talazoparib Sensitive : C4
CLDN6 expression	Testicular Cancer	CLDN6 expression	Testicular Cancer	IMAB027-vcMMAE Sensitive: D – Preclinical IMAB027-vcMMAE Sensitive : D	IMAB027-vcMMAE Sensitive: D – Preclinical IMAB027-vcMMAE Sensitive : D

Testicular Cancer

Associations(22)

Associations
(22)